Omeros plunges deep­er af­ter FDA re­jects rare dis­ease drug, ask­ing for more in­for­ma­tion

Omeros prac­ti­cal­ly warned in­vestors that a com­plete re­sponse let­ter was com­ing when it dis­closed that the FDA found de­fi­cien­cies in its BLA for nar­so­plimab. But …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER